B
Bristi Basu
Researcher at University of Cambridge
Publications - 101
Citations - 2079
Bristi Basu is an academic researcher from University of Cambridge. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 22, co-authored 85 publications receiving 1397 citations. Previous affiliations of Bristi Basu include Cambridge University Hospitals NHS Foundation Trust & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate and magnetic resonance imaging.
James T. Grist,Mary A. McLean,Frank Riemer,Rolf F. Schulte,Surrin S. Deen,Fulvio Zaccagna,Ramona Woitek,Charlie J. Daniels,Joshua D. Kaggie,Tomasz Matys,Ilse Patterson,Rhys Slough,Andrew B. Gill,Anita Chhabra,Rose Eichenberger,Marie-Christine Laurent,Arnaud Comment,Jonathan H. Gillard,Alasdair Coles,Damian J. Tyler,Ian B. Wilkinson,Bristi Basu,David J. Lomas,Martin J. Graves,Kevin M. Brindle,Ferdia A. Gallagher +25 more
TL;DR: Imaging normal brain metabolism with hyperpolarized [1–13C]pyruvate and subsequent quantification, have important implications for interpreting pathological cerebral metabolism in future studies.
Journal ArticleDOI
Imaging breast cancer using hyperpolarized carbon-13 MRI.
Ferdia A. Gallagher,Ramona Woitek,Ramona Woitek,Mary A. McLean,Andrew B. Gill,Raquel Manzano Garcia,Elena Provenzano,Frank Riemer,Joshua D. Kaggie,Anita Chhabra,Stephan Ursprung,James T. Grist,Charlie J. Daniels,Fulvio Zaccagna,Marie-Christine Laurent,Matthew Locke,Sarah Hilborne,Amy Frary,Turid Torheim,Chris Boursnell,Amy Schiller,Ilse Patterson,Rhys Slough,Bruno Carmo,Justine Kane,Heather Biggs,Emma Harrison,Surrin S. Deen,Andrew J. Patterson,Titus Lanz,Zoya Kingsbury,Mark T. Ross,Bristi Basu,Richard D. Baird,David J. Lomas,Evis Sala,James Wason,James Wason,Oscar M. Rueda,Suet-Feung Chin,Ian B. Wilkinson,Martin J. Graves,Jean Abraham,Fiona J. Gilbert,Carlos Caldas,Kevin M. Brindle +45 more
TL;DR: Imaging of hyperpolarized [1-13C]pyruvate metabolism in breast cancer is feasible and demonstrated significant intertumoral and intratumoral metabolic heterogeneity, where lactate labeling correlated with MCT1 expression and hypoxia.
Journal ArticleDOI
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Daniele Biasci,Martin Smoragiewicz,Claire M. Connell,Claire M. Connell,Zhikai Wang,Ya Gao,James Thaventhiran,Bristi Basu,Bristi Basu,Lukasz Magiera,T. Isaac Johnson,Lisa Bax,Aarthi Gopinathan,Christopher Isherwood,Ferdia A. Gallagher,Maria Pawula,Irena Hudecova,Davina Gale,Nitzan Rosenfeld,Petros Barmpounakis,Elizabeta C. Popa,Rebecca Brais,Edmund Godfrey,Fraz Mir,Frances M. Richards,Douglas T. Fearon,Douglas T. Fearon,Douglas T. Fearon,Tobias Janowitz,Duncan I. Jodrell +29 more
TL;DR: In this article, the authors showed that CXCL12-stimulated CXCR4 inhibits the directed migration mediated by all of the immune cell types that participate in an integrated immune response.
Journal ArticleDOI
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.
Bristi Basu,Emma Dean,Martina Puglisi,Alastair Greystoke,Michael Ong,Wendy Burke,Maria Cavallin,Graham Bigley,Christopher Womack,Elizabeth A. Harrington,Stephen Green,Elisabeth Oelmann,Johann S. de Bono,Malcolm R Ranson,Udai Banerji +14 more
TL;DR: The recommended phase II dose for further evaluation of AZD2014 is 50 mg twice daily, and at this dose it has been possible to demonstrate pharmacologically relevant plasma concentrations, target inhibition in tumor, and clinical responses.
Journal ArticleDOI
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer.
Hemant M. Kocher,Bristi Basu,Fieke E. M. Froeling,Fieke E. M. Froeling,Debashis Sarker,Sarah Slater,Dominic Carlin,Nandita M. deSouza,Katja N. De Paepe,Michelle R. Goulart,Christine Hughes,Ahmet Imrali,Rhiannon Roberts,Maria Pawula,Richard Houghton,Cheryl Lawrence,Yathushan Yogeswaran,Kelly Mousa,Carike Coetzee,Peter Sasieni,Peter Sasieni,Aaron Prendergast,David Propper,David Propper +23 more
TL;DR: Re-purposing ATRA as a stromal-targeting agent with gemcitabine-nab-paclitaxel chemotherapy is safe and tolerable and this combination will be evaluated in a phase II randomized controlled trial for locally advanced PDAC.